glp 1 trial GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction What's next for GLP-1 innovation:

The specific timelines

Semaglutide and tirzepatide allow for albumin binding and resistance to DPP4 degradation, creating a significantly longer half-life (5 days for tirzepatide and 7 days for semaglutide) and thus a greater effect on receptors and downstream pathways in the central nervous, cardiovascular, digestive, and musculoskeletal systems as described below [37, 38]

This includes: Even modest weight loss, of 5 to 10% of your body weight, can lead to noticeable improvements in blood sugar control, cholesterol levels, and blood pressure

They were also published in reputable journals, so thats a plus

On its own, glucagon can raise blood sugar, but when balanced with GLP 1 and GIP activity, the combined effect aims to support fat loss while maintaining better overall metabolic control

Diabetic ketoacidosis should be treated with insulin [see WARNINGS AND PRECAUTIONS and WARNINGS AND PRECAUTIONS ]